ERD-308, a PROTAC Degrader of ER, Has Potential to Treat ER+ Breast Cancer Treatment
In previous blogs, I have introduced some compounds based on PROTAC technology, including SJFδ, MS4077, BSJ-03-123, A1874, HJB97, Olutasidenib. Today, I’d like to introduce another novel compound ERD-308 as a…